Key terms
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATRA news
Apr 01
7:30am ET
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
Apr 01
7:25am ET
Atara Biotherapeutics price target lowered to $2.30 from $4.80 at Stifel
Mar 31
10:20pm ET
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
Mar 29
4:43pm ET
Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
Mar 29
2:00am ET
Atara Biotherapeutics’ Profitability Hinges on Partners’ Success with Ebvallo Amid Market Challenges
Mar 28
4:06pm ET
Atara Biotherapeutics (ATRA) Gets a Buy from TD Cowen
Mar 01
8:00am ET
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA), Moderna (MRNA) and Madrigal Pharmaceuticals (MDGL)
Feb 29
9:21am ET
FDA clears Atara’s IND application in LN for allogeneic CAR T therapy ATA3219
Feb 24
10:07am ET
Atara Biotherapeutics Restructures, CMO Transitions to Consultant
Feb 14
9:09am ET
Atara Biotherapeutics submits IND for ATA3219 to treat Lupus Nephriti
Feb 05
10:51am ET
Biotech Alert: Searches spiking for these stocks today
Feb 01
5:08am ET
Atara Biotherapeutics, Pierre Fabre announce publication of ALLELE data
Jan 31
6:35pm ET
Atara Biotherapeutics’ tabelecleucel meets primary endpoint in Phase 3 study
Jan 08
9:38am ET
Atara Biotherapeutics sells 27.272M shares at 55c in registered direct offering
Jan 08
9:09am ET
Atara Biotherapeutics announces $15M registered direct offering
No recent press releases are available for ATRA
ATRA Financials
Key terms
Ad Feedback
ATRA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATRA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
